Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanimilast (CHF6001) in uncontrolled asthma
NCT06029595Phase 2Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Nov 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of tanimilast in asthma, sponsored by Chiesi Farmaceutici S.p.A.. Started Nov 2023; status: terminated.
02
Drugs
tanimilast
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06029595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06029595.